A trial drug called RLF-100 or aviptadil has been raising hopes in the fight against the coronavirus outbreak. The COVID-19 pandemic has left global health systems and economies reeling. More than a dozen severely ill COVID-19 patients recovered rapidly from respiratory failure after receiving the RLF-100 treatment, according to an update from the companies behind the trial drug.
Currently, RLF-100 or aviptadil is in a Phase 2/3 clinical trial. Regulators have cleared the drug as an emergency treatment for coronavirus patients. Specifically, RLF-100 is being given to COVID-19 patients who are too sick to take part in the clinical trial.
Doctors from Houston Methodist Hospital reported promising results after using the trial drug. A COVID-19 patient received RLF-100 as an emergency treatment and quickly recovered from respiratory failure. The 54-year-old man received RLF-100 treatment for four days. He caught COVID-19 while being treated for a lung transplant-related issue.
Since then, more than 15 other COVID-19 patients have recovered from severe respiratory failure after being treated with RLF-100 or aviptadil.
In addition to success with RLF-100 as an emergency COVID-19 treatment, an independent laboratory assessment in Brazil also found that RLF-100 blocked coronavirus replication in human lung cells.
What is RLF-100 or aviptadil?
RLF-100 or aviptadil is a formulation of Vasoactive Intestinal Polypeptide (VIP). The FDA cleared aviptadil for human trials in 2001, while the European Medicines Agency gave approval in 2005.
Swiss drug developer Relief Therapeutics Holding, formerly Mondo Biotech, has a patent to RLF-100 (aviptadil). In 2001, Mondo Biotech received FDA Orphan Drug Designation for aviptadil to treat Acute Respiratory Distress Syndrome. In 2005, the FDA granted Orphan Drug Designation for aviptadil to treat Pulmonary Arterial Hypertension.
In 2007, the European Medicines Agency granted Orphan Drug Designation for aviptadil to treat sarcoidosis. The previous year, the European Medicines Agency awarded Orphan Drug Designation to aviptadil to treat acute lung injuries.
RLF-100 (aviptadil) carries Investigational New Drug licenses for human trials from the FDA and European drug regulators.
Currently, the RLF-100 (aviptadil) COVID-19 trial has enrolled dozens of participants. In July, the FDA granted fast-track designation for the COVID-19 trial.
Which company makes RLF-100?
Relief Therapeutics, which holds the patent to aviptadil, has partnered with pharmaceutical company NeuroRx to develop RLF-100. While Relief Therapeutics is headquartered in Geneva, Switzerland, NeuroRx is based in the U.S. and Israel.
The clinical trial that Relief Therapeutics and NeuroRx has been conducting on RLF-100 for COVID-19 treatment seeks to confirm the results from hospitals that used the drug as an emergency treatment.
Where can you purchase stocks related to aviptadil?
Relief Therapeutics stock is listed on the SIX Swiss Exchange and trades under the ticker symbol RLF. Currently, Relief Therapeutics trades at 0.040 Swiss francs or $0.040 per share. NeuroRx, the other company involved in RLF-100 (aviptadil), is held privately.